Implementation Could Be Tough For Rebate Executive Order
On July 24, the Trump administration released three executive orders, which call for regulations allowing drugs to be imported from other countries, requiring Federally Qualified Health Centers to make insulin and epinephrine available to low-income people at the discounted prices set by the 340B Drug Pricing Program, and removing safe harbor protections under the Anti-Kickback statue for prescription drug rebates in Medicare Part D. A fourth executive order would tie drug prices to their list prices in countries with Most Favored Nation status, but it has not yet been released.
Industry experts and trade groups have been particularly critical of the executive order that directs HHS to resurrect the so-called rebate rule, which the administration withdrew in 2019.
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
